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L'archive ouverte pluridisciplinaire HAL, est destinée au dépôt età la diffusion de documents scientifiques de niveau recherche, publiés ou non, emanant desétablissements d'enseignement et de recherche français ouétrangers, des laboratoires publics ou privés. [Campagnoli et al., 2004] . The other bone marrow cell lineages are only rarely suppressed. Erythrocytes in DBA patients frequently express fetal hemoglobin (HbF) and erythrocyte adenosine deaminase (eADA) activity, a crucial enzyme of the purine salvage pathway, is elevated in 85% of cases [Glader and Backer, 1988] . DBA is associated with an increased risk of malignancies, especially hematopoietic neoplasms and osteogenic sarcomas . In 30% to 47% of cases patients show physical malformations involving head, thumb, heart and urogenital system [Lipton, 2006] . Prenatal or postnatal growth retardation independent of steroid therapy is also often present.
F
The incidence of DBA is around 6 per 1 million live births [Campagnoli et al., 2004] . Most cases are sporadic, but the disease can be inherited with an autosomal dominant pattern.
Penetrance is incomplete and expressivity widely variable, even in patients from the same family [Campagnoli et al., 2004] . First-line therapy in DBA patients is steroid treatment.
Although 80% of patients have an initial steroid response, less than half the patients can be maintained on a safe and effective dose. Thus many of these initial responders may experience temporary or definitive steroid-resistance of dose limiting toxicity . Patients who do not respond to steroids undergo chronic blood transfusions and need iron chelation to avoid secondary hemochromatosis. Preliminary data suggest that patients with DBA are more likely to develop iron overload than patients with thalassemia, another disease treated with chronic transfusions [Roggero et al., 2009] . Twenty percent of patients inexplicably achieve remission [Lipton, 2006] . DBA can be treated successfully by allogeneic bone marrow or stem cell transplantation, but the mortality from infections, graft-versus-host disease and graft failure is significant, especially for unrelated donor transplants [Roy et al., 2005; Vlachos et al., 2008] .
The first DBA gene, ribosomal protein (RP) S19, was identified in 1999 [Draptchinskaia et al., 1999] and is mutated in about 25% of patients [Willig et al., 1999; Campagnoli et al., 2008] . Mutations in an increasing number of other genes encoding RPs of the small (RPS24,
RPS17, RPS7, RPS10, RPS26
) and large (RPL35A, RPL5, RPL11) ribosomal subunits have been recently described in DBA patients [Gazda et al., 2006; Cmejla et al., 2007; Farrar et al., 2008; Gazda et al., 2008; Doherty et al., 2010] . All mutations are present on a single allele, pointing to autosomal dominant inheritance haploinsufficiency. DBA is unquestionably a ribosomapathy, a term initially proposed for dyskeratosis congenita [Luzzatto and Karadimitris, 1998 ].
In eukaryotes, the ribosome is composed of four different ribosomal RNAs (rRNAs) and 79 ribosomal proteins. While 5S rRNA is transcribed by RNA polymerase III, 28S, 5.8S and 18S
rRNAs are processed from a 45S precursor transcribed by RNA polymerase I. The maturation of pre-rRNA occurs in the nucleolus through a complex pathway involving both endo-and exonucleases that remove external and internal transcribed sequences (ETS and ITS). During these steps, the 45S pre-RNA associates with ribosomal proteins, ribonucleases, RNA helicases, small nucleolar RNPs (snoRNPs) and other accessory factors, to form 90S preribosomes. During the maturation process, the 90S pre-ribosome is separated into pre-40S and pre-60S subunits that are exported to the cytoplasm where maturation is completed [Tschochner and Hurt, 2003] 
VARIANTS

RPS19
The RPS19 gene (OMIM 603474; locus 19q13.2) was the first DBA gene that was discovered and is the most frequently mutated in patients. It comprises 6 exons and spans 11 kb. The first exon (372 bp) is not included in the coding DNA sequence (CDS) region, while the other five (435 bp) encode a protein of 145 amino acids (MW ~16 kDa).
Eighty-seven distinct mutations have been previously described in RPS19 gene [most reviewed in Campagnoli et al., 2008] . We here report 42 additional mutations: 11 missense, 3 nonsense, 18 deletions and/or insertions, 10 splice-site defects (Table 1) . Overall 129 distinct 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
RPL5
The human RPL5 gene (OMIM 603634; locus 1p22.1) consists of eight exons and spans 9.8 kb. The primary transcript is 1031 nt long and encodes a 297-aa protein (MW ~34.2 kDa) component of the 60S ribosomal subunit.
Heterozygous mutations in RPL5 gene have been reported in DBA patients Cmejla at al., 2009; Quarello at al., 2010] . Gazda et al. showed mutations in 18 of 196 DBA probands (9%) and in six additional family members , for a total of 24 individuals; Cmejla et al. studied 28 Czech families and identified sequence changes in 8 DBA patients from 6 families (21.4%) [Cmejla et al., 2009] ; Quarello et al. reported mutations in 12 out of 92 (13%) unrelated Italian probands [Quarello et al., 2010] . In this paper we are adding 10 new mutations found in 12 patients (Table 1) and two patients carrying two previously described mutations. The total number of patients with mutations in RPL5 is 58: 21 have a de novo mutation, 10 are familial cases. Thirty-nine mutations are distinct and are distributed as follows: 6 missense, 7 nonsense, 21 small deletions and/or insertions, 5 splice-site defects.
Ninety-five polymorphisms are listed in NCBI SNP database. There are multiple processed pseudogenes of RPL5 gene dispersed through the genome: three of them are annotated as 'validated' in NCBI Gene database.
RPL11
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Human Mutation
Twenty-three distinct mutations in 34 DBA patients have been previously described Cmejla at al., 2009; Quarello at al., 2010] ; three new mutations are reported here for the first time ( Table 1 ). The 26 mutations are classified as follows: 1 missense, 2 nonsense, 17 small deletions and/or insertions, and 6 splice-site defects. The total number of patients with mutations is 37: 12 carry a de novo mutation, whereas 7 are familial cases.
Fifty-seven polymorphisms are reported in NCBI SNP database and five pseudogenes are annotated in NCBI Gene database as 'inferred'.
RPL35A
The RPL35A Farrar et al. [2008] reported five mutations: one missense, one nonsense, one small deletion and two deletions of a complete allele. They are all considered pathogenic. The missense mutation c.97G>A, which creates a cryptic splice donor site within exon 3, was also found in the proband's father and sister, both showing isolated macrocytosis. Inheritance was not tested in the remaining cases [Farrar et al., 2008] .
The RPL35A gene has 45 polymorphisms listed in NCBI SNP database and only one pseudogene annotated as 'validated' in NCBI Gene database.
RPS24
The RPS24 (OMIM 602412; locus 10q22-q23) gene comprises 6 exons and spans 8 kb. Its three isoforms are expressed as splice variants: S24a or variant 1 (615 bp), S24c or variant 2 , 1996; Gazda et al., 2006] .
Three RPS24 mutations in a total of 8 DBA patients [Gazda et al., 2006] have been previously reported in the DBA Mutation Database. Recently Quarello et al. and Badhai et al. showed two further changes in RPS24 gene: a small deletion and a missense mutation [Quarello et al., 2010; Badhai et al., 2009] . Additionally, we identified an unpublished splice donor variant (Table 1 ). In total 6 mutations are reported for this gene: one missense, two nonsense, one small deletion and two splice-site defects. In total, 12 patients were found mutated in this gene: only one has a de novo mutation, whereas 5 carry an inherited mutation.
Eighty-two polymorphisms are listed in NCBI SNP database and only one RPS24 pseudogene is annotated as 'validated' in NCBI Gene database.
RPS17
The RPS17 gene (OMIM 180472) is located on chromosome 15 (locus 15q). It encompasses five exons and spans 3.7 kb. The RPS17 mRNA is 562 nt long and encodes for a 135-amino acid protein (MW ~15.5 kDa). Two different sequence changes eliminating the natural start site for protein synthesis were found in this gene by Cmejla et al. in 2007 and Song et al. in 2010 identified a new mutation among 196 tested probands; it is a deletion of two nucleotides causing a frameshift. All mutations are de novo.
The RPS17 gene has 30 polymorphisms listed in NCBI SNP database and has two 'validated' pseudogenes in NCBI Gene database.
RPS7
The RPS7 gene (OMIM 603658; locus 2p25) consists of 7 exons spanning 5.6 kb. The predicted size of the primary transcript is 745 bp encoding a 194-aa protein (MW ~22 kDa). A donor splice-site mutation in intron 2 was found in a single DBA patient by Gazda and collaborators . The inheritance was not tested.
Eighty-three polymorphisms are listed in NCBI SNP database for this gene and only one pseudogene is annotated as 'validated' in NCBI Gene database.
RPS26
The RPS26 gene (OMIM 603701) is located on chromosome 12 (locus 12q13) and has four exons spanning 2.32 kb. It results in a transcript of 699 bp encoding a 115-amino acid protein (MW ~12.9 kDa).
Recently, Doherty and collaborators identified 8 distinct mutations in 13 DBA patients: 5 carry a de novo mutation, whereas 3 are familial cases [Doherty et al., 2010] . Mutations in this gene were identified in about 6.4% of the overall DBA population and are distributed as follows: 4 missense, one insertion and 3 splice-site defects.
The RPS26 gene has 64 polymorphisms listed in NCBI SNP database and 4 pseudogenes annotated as 'validated' in NCBI Gene database.
RPS10
The RPS10 gene (OMIM 603632; locus 6p21.31) encompasses 6 exons spanning 8.65 kb. The predicted size of the primary transcript is 636 bp encoding a 165-aa protein (MW ~18.8 kDa).
Mutations in this gene were identified in about 2.6% of the overall DBA population [Doherty et al., 2010] . Specifically three distinct sequence changes in 5 DBA probands have been reported: one missense, one nonsense and one insertion. One mutation is de novo, whereas in the other cases the inheritance was not ascertained [Doherty et al., 2010] .
The RPS10 gene has 88 polymorphisms reported in NCBI SNP database and 3 'validated' pseudogenes listed in NCBI Gene database. 
MUTAGENESIS MECHANISMS
Common mutagenesis mechanisms that generate point mutations include slippage, that causes small indels, and cytosine-guanine (CpG) dinucleotide methylation followed by spontaneous deamination, which causes G>A or C>T transitions. We evaluated the involvement of these mechanisms in DBA by comparing each mutant sequence to the wild-type gene sequence and by observing the context in which a mutation occurred. We found that 57 out of 87 indels in DBA patients are consistent with a slippage mechanism. The frequency of the different substitution classes is 64 transitions versus 50 transversions. Out of 64 transitions, we identified 15 mutations occurring within CpG dinucleotides.
A rare mechanism of mutagenesis is interlocus gene conversion arising from transfer of genetic information between highly homologous genes. Well-known diseases caused by this process are steroid 21-hydroxylase deficiency [Morel et al., 1989] and Shwachman-Diamond syndrome [Boocock et al., 2003] . In these cases the donor sequence is a nearby pseudogene resulting from a recent duplication. To investigate the occurrence of pseudogene-mediated gene conversion in DBA, we retrieved pseudogene sequences of the most frequently mutated RPs (RPS19, RPL5 and RPL11) annotated as 'validated' and/or 'inferred' in NCBI Gene database; all of them were intronless. We aligned them with their respective RP gene sequences and looked at 5bp on each side of the mutation, searching for a correspondence between the pseudogene and the mutated sequence. We found only 6 mutations possibly due to gene conversion: 4 in RPS19, 1 in RPL5 and 1 in RPL11 ( Table 2 ). The pseudogenes are all located on different chromosomes, as compared to the respective genes. Two mutations in RPS19 are identical to the corresponding sequence of pseudogene RPS19P2 located on chromosome 1. Obviously, we could not exclude that the same changes arose independently in the gene and in the pseudogene. In any case, our results show that gene conversion does not play a major role in generating mutations in RPS19, RPL5 and RPL11. In conclusion, the most frequent mutagenic mechanism observed in DBA patients appears to be slippage, followed by transitions occurring at CpG dinucleotides.
BIOLOGICAL RELEVANCE
Several studies have addressed the effects of DBA mutations showing that they can lead either to a reduction of RP mRNA or to the production of ribosomal proteins with defective stability and/or localization. In all these cases, mutations cause haploinsufficiency which in turn interferes with the biogenesis of the large or the small ribosomal subunit. These defects are due to aberrant rRNA maturation at different steps, depending on the affected RP [Flygare et al., 2007; Choesmel et al., 2007; Idol et al., 2008; Gazda et al., 2008; Farrar et al., 2008; Doherty et al., 2010] . Here, we briefly revisit the biological function of each DBA RP and the effects of their mutations.
RPS19. RPS19 mutations are associated with a defect in the maturation of 18S rRNA resulting in the accumulation of 21S pre-rRNA precursors [Flygare et al., 2007; Choesmel et al., 2007; Idol et al., 2008] . All of these mutations cause loss of function and some have been functionally characterized. Extensive functional data were recently reviewed by Campagnoli et al. in this journal . Furthermore Crétien and collaborators reported the study of the subcellular localization of several RPS19 mutants fused to green fluorescent protein (GFP) [Crétien et al., 2008] [Crétien et al., 2008] . Another mutation was recently investigated for its functional consequences by Badhai and collaborators, who reported that primary fibroblasts from a DBA patient with a RPS19 acceptor splice-site mutation (c.72-2A>C) showed reduced proliferative capacity due to G1 arrest [Badhai et al., 2009] .
RPL5. RPL5 has been implicated in nucleocytoplasmic transport of 5S rRNA prior to its assembly into the large ribosomal subunit [Steitz et al., 1988] . RPL5 specifically binds to this rRNA through the domains located at both the amino terminus and the carboxyl terminus [Michael and Dreyfuss, 1996] . It has been shown that the perturbation of ribosomal biogenesis by impaired rRNA synthesis, processing, or ribosome assembly, triggers the direct knockdown induces reduction of free 60S subunit and formation of half-mer polysomes .
RPL11.
In yeast, Rpl11 forms a subcomplex with Rpl5 and 5S rRNA that is recruited into nascent ribosomes at an early step [Zhang et al., 2007] . In human cells, RPL11 appears to have a similar role in ribosome biogenesis but also functions to suppress the transcriptional activity of c-Myc and plays a feedback regulatory role in coordinating c-Myc level and [Fumagalli et al. 2009 ]. The ubiquitin-like molecule NEDD8, that controls RPL11 stability and subcellular localization, plays an important role in the regulation of RPL11 signaling to p53 [Sundqvist et al., 2009] . In zebrafish rpl11 knockdown activates the p53 pathway and disrupts the normal embryonic development through a p53-mediated apoptotic response [Chakraborty et al., 2009 ]. Gazda and collaborators showed that mutations in RPL11, c.314_315delTT, IVS1+2t>c, IVS2-1g>a, IVS4+1g>t, lead to accumulation of the precursors of 28S and 5.8S rRNAs, similar to that of mutations in RPL5 . rRNA compared to healthy controls [Farrar et al., 2008] .
RPS24. RPS24, like RPS19, is essential for the production of the small ribosomal subunit, as displayed by the reduction of 40S subunits and 80S monosomes in polysomal profiles of RPS24-depleted cells . Lymphoblastoid cells from three patients with mutations in RPS24 (p.Gln106X, p.Arg16X, deletion N2-Q22) showed delayed maturation of 30S pre-rRNA with a corresponding decrease in 21S and 18S-E pre-rRNAs. Accumulation of the 30S pre-rRNA suggests that RPS24 is required for the maturation of both the 5′ and 3′ .
RPS26. RPS26 can regulate its own expression by binding its pre-mRNA and suppressing its splicing [Ivanov et al., 2005] . Northern blot analysis showed that depletion of RPS26 in HeLa cells leads to the accumulation of 43S, 26S and 18S-E pre-rRNAs, pointing to defective cleavage at both ends of 18S. The same phenotype was present in lymphoblastoid cells derived from RPS26 mutated patients (c.1A>T, c.1A>G in two different probands, c.97G>A
and IVS1+1g>c) [Doherty et al., 2010] .
RPS10. Analysis of RPS10 depleted HeLa cells and RPS10 mutated lymphoblastoid cells
(c.260_261insC and c.337C>T in three different probands) revealed a pre-rRNA processing phenotype similar to RPS26 [Doherty et al., 2010] . [Faivre et al., 2006] .
Genotype-Phenotype Correlation
Genotype-phenotype correlations were evaluated in all patients reported in the DBA Mutation Database. They represent approximately 50% of the total number of DBA patients. Clinical description was not available for a few patients thus each analysis was calculated only for patients that had the specific clinical information.
The statistical analysis was performed by considering the following parameters: growth retardation, craniofacial malformation (other than cleft lip and palate), cleft lip and/or palate, upper limb abnormalities, flat thenar muscle, malformed thumb, triphalangeal thumb, heart anomalies, genitourinary anomalies, presence of any type of malformation including short stature, any type of malformation with the exclusion of short stature, multiple malformations, mental retardation, small for gestational age (SGA), response to steroids (Table 3) .
Hematological information was not considered because clinical data reported in old publications were not updated. The risk connected with carrying a mutation in a specific RP relative to patients carrying mutations in the other eight RP genes studied was obtained by using logistic regression and odds ratio (OR) and 95% CI were calculated. P values less than 0.05 were considered statistically significant. Data were analyzed with the SAS software 
Variable expressivity
Variable expressivity is shown for all RP gene mutations. Possible mechanisms underlying variable expressivity include an influence of modifier genes and environmental factors.
Stochastic factors are invoked in the case of non concordance for malformations in monozygous twins [Campagnoli et al., 2004] . Potential modifier genes could be genes involved in modulating the level of expression of RP genes or other genes involved in ribosome biogenesis. A patient harboring mutations in two different RP genes, RPL5 and RPS24, was reported by Quarello et al. (2010) . In this case, the malformation phenotype was likely due to RPL5, since the patient carried hand malformation, often associated with RPL5 mutations. Moreover RPL5 mutation was de novo and the parent carrier of the RPS24 missense mutation did not show malformations. These aspects suggest that the RPS24 [Crétien et al., 2010] .
DATABASE
The need for a comprehensive collection of all mutations in DBA genes, as well as of their functional consequences and clinical phenotypes, prompted us to create and maintain the DBA Mutation Database (http://www.dbagenes.unito.it) [Boria et al. 2008] . It is founded on the Leiden Open (source) Variation Database (LOVD) system that was upgraded to the latest version, LOVD 2.0 build 25, released in March 2010 [Fokkema et al., 2005] .
The first version of the database included only three DBA genes, RPS19, RPS24 and RPS17, and 86 distinct disease-causing mutations. The database has been updated with the newly described DBA genes: RPL5, RPL11, RPL35A, RPS7, RPS26, RPS10, and now comprises a total of 220 distinct pathogenetic mutations, distributed as follows: 52 missense, 27 nonsense, 87 small deletions and insertions, 14 large deletion and rearrangements and 40 splice-site defects ( Table 4) . Out of the 134 newly added sequence changes, 78 were previously published while 56 are reported here for the first time. Overall, the database includes data for 355 patients, all carrying RP mutations.
According to the basic structure of the LOVD database scheme, each DBA gene has its own homepage providing general gene and database information, access to allelic variant tables, search tools for browsing data and links to external gene-related resources, such as NCBI SNP database, MIM, NCBI Entrez, HGMD (Supp. Figure S1 ). Furthermore links to schematic drawings showing the location of the pathogenetic variants in relation to the gene (Supp. Figure S2 ) and, when available, to the protein structures are included. [Wildeman et al., 2008] .
All mutations are described according to the Human Variation Society (HGVS) nomenclature [den Dunnen and Antonarakis 2000] and their pathogenicity was established according to the
All available data relative to each mutation are provided in the "Variants" section and include the exact molecular description at DNA and protein levels, the clinical features of the corresponding patients, literature references and details on the detection methods. Consistent with the functional classification proposed for RPS19 by Campagnoli et al. (2008) , information about functional consequences of mutations on mRNA and protein are reported.
Compared to the previous database version, it is now possible to specify the potential molecular mechanism leading to each allelic variant ("Molecular Mechanisms" column) and for each patient the clinical complications ("Complications" column). Furthermore, we substituted the "Occurrence" column with "Variant Origin" that describes the inheritance of the mutation in an exhaustive way. Further details can be found at the database web site.
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DIAGNOSTIC RELEVANCE
FUTURE PROSPECTS
The ribosomal basis of DBA is evident. So far about 50% of DBA patients may be characterized using the four most commonly mutated genes: RPS19, RPL5, RPL11, RPS26. It is expected that other RP genes may be mutated in the remaining patients. For this reason the DBA community has started a large project focused at sequencing each of the 79 RP genes in every DBA patient.
However, sequencing is tedious and time-consuming. An easy and quick diagnostic assay would be of great help to clinical hematologists: the perfect assay should be able to diagnose all DBA patients, independently of the gene affected. A genetic or functional abnormality shared by all patients may be exploited to generate a diagnostic assay.
The definition of the molecular basis of DBA has also opened the road to molecular therapy.
Gene therapy looks promising since even a small increase of RP expression may be helpful to resolve the bone marrow failure thereby making this disease a reasonable target for this treatment [Flygare et al., 2008] . Treatment with leucine has been proven helpful in rare cases but large clinical trials are necessary to ascertain if its effect may be general or gene specific.
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METHODS
MUTATION DETECTION AND PATHOGENICITY ASSESSMENT
Mutation detection has been performed using automatic sequencing. For each group details can be found on their previous papers Cmejla at al., 2009; Quarello at al., 2010; Proust et al., 2003 ].
Generally, the complete coding sequence and exon-intron boundaries have been sequenced to eliminate the possibility of the presence of other mutations. Verification has been performed in keeping with the journal's requirements. In particular, all mutations have been confirmed on a second sample and on a second PCR product. In absence of biochemical data, pathogenicity of missense mutations have been established by at least two methods. In turn, the following methods were used: linkage to disease in a family, concurrent appearance of the phenotype with a de novo mutation, or determination that the mutation is absent among at least 50 normal individuals (100 alleles) or involves a highly conserved amino acid. In some cases the Polyphen algorithm has been used. Otherwise pathogenicity is reported as uncertain in the Database.
FIGURES
SUPPLEMENTAL FIGURE S1. The main page of the RPS19 mutation database.
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